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BACKGROUND: Barrett esophagus (BE) caused by gastroesophageal reflux disease can lead to esophageal cancer.
The success of endoscopic treatments with BE eradication depends on esophageal anatomy and
post-treatment acid exposure.
STUDY DESIGN: Between January 2008 and December 2009, 10 patients were selected for combination treat-
ment of BE using laparoscopic anti-reflux surgery and endoscopic radiofrequency ablation.
Retrospective review of preoperative, procedural, and postoperative data was performed.
RESULTS: Seven study patients had a pathologic diagnosis of nondysplastic BE and 3 patients had a
diagnosis of low-grade dysplasia. Average length of BE lesions was 6.4 4.8 cm. Procedure time
averaged 154.4  46.4 minutes. At the time of surgery, the mean number of ablations per-
formed was 4.39  1.99. Six patients were noted to have major hiatal hernias requiring
reduction. Five patients (80%) had 100% resolution of their BE at their first postoperative
endoscopy. The remaining 3 patients had a 50% resolution and underwent subsequent
endoscopic ablation. Symptomatic results revealed that 4 patients had substantial dysphagia to
solids and other symptoms were minimal. Two patients were noted to have complications
related to the ablative treatments. One stricture and 1 perforation were observed.
CONCLUSIONS: Endoscopic radiofrequency ablation of BE at the time of laparoscopic fundoplication is feasible
and can effectively treat BE lesions. A single combined treatment can result in fewer overall
procedures performed to obtain BE eradication. (J Am Coll Surg 2011;213:486–492. © 2011
by the American College of Surgeons)
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cEsophageal cancer has the fastest growing incidence rate of
all cancers in the United States and Western Europe, in-
creasing 400% during the past 35 years.1-4 Barrett esopha-
gus (BE) represents a marker for the potential development
of esophageal adenocarcinoma. This condition develops
when gastroesophageal reflux damages the distal esopha-
geal squamous mucosa and the resulting injury heals by a
metaplastic process.4,5 BE can progress in a stepwise fashion
rom intestinal metaplasia to low-grade dysplasia to high-
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Published by Elsevier Inc.rade dysplasia to carcinoma in situ and, ultimately, inva-
ive adenocarcinoma. The mechanisms of this progression
re not completely understood.
With current understanding of BE’s relationship to
astroesophageal reflux disease and its risk of cancer, we
elieve that treatment of dysplastic BE should be 2-fold,
e, attention to the dysplastic mucosa and effective treat-
ent of chronic gastric reflux exposure that leads to such
hanges.
Radiofrequency ablation (RFA) has been safely and ef-
ectively applied to BE with and without dysplastic
hanges.6-9 It usually requires 2 to 3 ablation sessions to
achieve complete eradication of BE. However, anatomic
distortion of the esophagus from large hiatal hernias, stric-
tures, esophageal dilation or tortuosity, shortened-
esophagus, or, possibly, a previous fundoplication (Fig. 1),
can make it more difficult to achieve effective ablation.10-12
In these scenarios, RFA of BE can require multiple at-
tempts or be impossible to accomplish.
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velop BE remains unchanged, prevention of reflux seems
mandatory to prevent recurrence. Optimal control of re-
flux after ablation, however, has not been defined. Current
options include lifetime high-dose acid suppression or anti-
reflux surgery (ARS). The role of ARS certainly has theo-
retical appeal because it provides an absolute barrier to all
gastric contents and there is ample evidence that acid alone
is not the causative agent of BE or dysplasia. If one accepts
the idea of adding an ARS to BE ablation, the question of
the timing of the 2 procedures arises. For example, al-
though ARS before ablation can straighten the esophagus
and cure esophagitis and strictures, the fundoplication it-
self can interfere with effective RFA by obscuring the land-
marks of the gastroesophageal junction or making access to
the distal-most segments of the metaplasia more difficult.
Performing ARS after an ablation can also be more difficult
because of transmural inflammatory changes, or complete
ablation can never be possible because of the anatomical
distortion of the esophagus (angulation, dilatation, short-
ening) related to hiatal herniation.13
We hypothesize that performing endoscopic RFA of BE
at the time of ARS would be a safe and effective method
that can reduce the number of treatments needed to erad-
icate the metaplasia by reducing the hernia and straighten-
ing the esophagus, as well as providing the best chance of
preventing future BE recurrence.
METHODS
This study involved the retrospective review of patient
charts and information that was prospectively collected for
an IRB-approved data registry containing patients who had
endoscopic balloonbased esophageal RFA. All proce-
dures were performed between January 2008 and Decem-
ber 2009.
Patients
Two groups of patients were included. The first included
patients who were scheduled for ARS because of either
failure or dislike of chronic medical therapy and who had
endoscopic and histologic presence of BE with no or low-
grade dysplasia. Patients with high-grade dysplasia were
Abbreviations and Acronyms
ARS  anti-reflux surgery
BE  Barrett esophagus
RFA  radiofrequency ablationexcluded from selection in this group, as the presence of afundoplication might compromise future oncologic resec-
tion and reconstruction if needed.
The second group of patients included those who orig-
inally had biopsy-proven BE with either low- or high-grade
dysplasia and who were considered failures to ablate (3
attempts) because of anatomic distortion of the esophagus
from dilation, tortuosity, or hiatal hernias; and those who
currently had either nondysplastic or low-grade dysplasia
on biopsy. Likewise, patients with persistent high-grade
dysplasia were excluded and were instead considered for
minimally invasive esophagectomy.
Presenting and procedural data
Demographic data were prospectively collected including
age, sex, and medical history. Histopathology in the ab-
sence of esophagitis, 24-hour pH, and esophageal mano-
Figure 1. Contrast study of patient with long-standing gastroesoph-
ageal reflux disease, paraesophageal hernia, and chronic esopha-
geal mucosal scarring.metric testing were recorded in an Access-based (Mi-
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488 Goers et al Treatment of Barrett Esophagus J Am Coll Surgcrosoft) database. Baseline BE measurements were taken
from the first endoscopy. Endoscopy was performed using
white light and narrow-band imaging. The endoscopic bi-
opsy protocol included 4 quadrant biopsies taken at 2-cm
intervals and all nodular areaswere removedwith endoscopic
submucosal resection (EMR). Dysplasia was recorded based
only on biopsies taken in the absence of acute inflammation.
Presence, type, and size of hiatal hernia were also recorded. At
the time of surgical procedure, information about the length
of ablation, type of electrode, and details of treatment were
recorded from the operative report.
Surgical procedure
All procedures were done under general anesthesia in the
supine position using 5 laparoscopic ports.Mediastinal dis-
sections were performed with the end point of the gastro-
esophageal junction lying 3 cm below the hiatus (Fig. 2).
After mobilization of the distal esophagus and stomach, the
esophagus was sized with a sizing balloon and an
appropriate-sized RFA ablation balloon (HALO360; Barrx
edical) was selected by a second surgeon performing en-
oscopy. After irrigating the esophagus with 1%
-acetylcysteine to remove mucous, the balloon ablation
atheter was inserted over a guidewire and ablation per-
ormed as the laparoscopic surgeon applied careful traction
o straighten and align the esophagus to maximize contact
f the ablation balloon. Two cycles of ablations were per-
ormed at either 10 J (no dysplasia) or 12 J (history of
ysplasia). Two patients with more localized and limited
isease had ablation with a endoscope-mounted electrode
HALO90; BarrxMedical) instead of the balloon electrode,
but using the same ablation protocol. Once the ablation
was completed, repair of any hiatal hernia was performed
Figure 2. (A) Extensive type II mediastinal di
agus and the gastroesophageal junction re
balloon electrode can contact esophageal muand a tailored fundoplication was performed.Postoperative care
All patients were admitted overnight and observed. Pa-
tients were placed on proton pump inhibitors and were
given liquid pain medication as needed. Those who had
concomitant performance of a paraesophageal hernia were
kept nothing per os overnight and underwent esophago-
gastric radiographic study with water-soluble contrast on
the first postoperative morning. If no leak was detected,
patients were started on a liquid diet. Those with minimal
hiatal hernias were started on a liquid diet the night of
surgery. All patients were instructed to continue the liquid
diet for 2 days, followed by a pureed diet for 2 weeks. The
patients were instructed to take a single-dose proton pump
inhibitor for the first 3 weeks after surgery to protect the
denuded distal esophagus.
Outcome measurements
A standardized gastrointestinal symptom assessment tool
was administered at each visit. Patients were followed up in
clinic at 2 weeks, 3 months, and 6 months and then yearly.
A focused physical examination was performed and any
complications or side effects from the surgery were re-
corded. Patients who had any severe symptoms at any visit
underwent appropriate studies and treatment at that visit.
Routine follow-up endoscopy was performed 2 to 3
months after the combination procedure to assess com-
pleteness of the ablation. Esophageal mucosa was examined
using white light and narrow-band imaging. Subjective
mapping of residual BE lesions’ length and circumferential
vs. focal nature were recorded in the endoscopic report.
Four quadrant biopsies were repeated at 2-cm intervals of
both normal-appearing mucosa and columnar mucosa us-
ing endoscopic jumbo forceps andwere sent in formalin for
pathology. Percentage of BE resolution was estimated by
ion allows straightening of the distal esoph-
ithin the abdomen. (B) The radiofrequency
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the integrity of the fundoplication was determined per our
usual protocol using endoscopy, high-resolution manome-
try, and 24-hour pH studies. A competent fundoplication
was defined as an intact wrap on endoscopic retroflection
(Hill grade 1) and/or normal acid exposure by 24-hour pH
tests (DeMeester score14.7). If BE was present at the 3-
r 6-month visit, the patient had an additional RFA at that
ime.
Data analysis
Data that was collected was stored in an IRB-approved
database that was developed and maintained by the princi-
pal investigator. The means of all of the continuous vari-
ables were compared using appropriate parametric or non-
parametric tests. Statistical analysis was performed using
Predictive Analytics Software (version 18.0; SPSS, Inc).
RESULTS
During the 24-month data collection period, 78 patients
with BE underwent treatment, of these, 15 patientsmet the
inclusion criteria to undergo concomitant endoscopic RFA
and laparoscopic fundoplication for the simultaneous
treatment of BE and gastroesophageal reflux disease. Of
these, 1 patient requested esophagectomy, 1 patient re-
jected the follow-up protocol, and 3 did not want a fundo-
plication. Therefore, 10 patients agreed to the combined
procedure.
Patients varied in age from 23 to 80 years old (Table 1).
Similarly, American Society of Anesthesiologists scores
were all 2, with the exception of a 23-year-old patient who
Table 1. Demographic and Preoperative Data of
Study Patients
Age, y, mean  SD 58  16.6
Body mass index, mean  SD 34  9
Male sex, n (%) 7 (70)
ASA, n (%)
1 1 (10)
2 9 (90)
Histology, n (%)
Nondysplastic 7 (70)
Low-grade dysplasia 3 (30)
GERD 10 (100)
Esophagitis 1 (10)
Preprocedure ablations, n (%)
None 3 (30)
Multiple 7 (4 –6)
ASA, American Society of Anesthesiologists; GERD, gastroesophageal reflux
disease.was scored as a 1.The average bodymass index of the groupwas in the category of obese (34  9), and no patient was
onsidered to be normal (interquartile range 26.138.0).
At the time of the study, all patients had biopsy-
onfirmed BE. Seven study patients had a pathologic diag-
osis of nondysplastic BE and 3 patients had a diagnosis of
ow-grade dysplasia. All 10 patients had abnormal 24-hour
H testing. All patients had high-resolution manometry
nd 1 patient had a profound primary esophageal dysmo-
ility. Only 1 patient had active esophagitis at the time of
iagnosis. Seven of the patients were considered to have
ailed RFA because of BE persistence despite multiple ab-
ation attempts (4 to 7 attempts).The other 3 were de novo
atients with long-segment BE (2 with low-grade dyspla-
ia, 1 without) who were seeking ARS for symptom control
ecause of failure of medical management.
Procedural data
The combined procedure time averaged 154.4  46.4
minutes (Table 2). At the time of surgery, 6 patients were
noted to have major hiatal hernias (type III) requiring
reduction and crural reconstruction. Nine patients un-
derwent 360-degree fundoplication and the patient with
poor esophageal motility had a 270-degree posterior
fundoplication.
The average length of BE lesions was 6.4  4.8 cm
(Table 2). Eighty percent required the 360-degree balloon
electrode for circumferential disease. The 90-degree
HALO electrode was used in 20% for more focused energy
application. One patient had both circumferential and fo-
cal islands of disease and required the use of both the 360-
degree and 90-degree electrodes. Of the 3 patients with
Table 2. Procedural Data of Study Patients
Length of procedure, min, mean  SD 154.4  46.41
Barrett’s esophagus length, cm, mean SD 6.4  4.78
blations performed during initial procedure, n,
mean  SD 4.39  1.99
undoplication, n (%)
Nissen 9 (90)
Toupet 1 (10)
resence of large hiatal hernia, n (%) 6 (60)
ircumferential lesions/360 balloon used, n (%) 8 (80)
alloon size, mm, n (%)
25 5 (50)
28 2 (20)
31 3 (30)
ocal lesions/HALO90 used, n (%) 3 (30)
Energy, J, n (%)
10 6 (60)
12 4 (40)dysplasia, all had energy applied at 12 J/cm2 3 with the
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electrode used varied. Fifty percent of patients required the
25-mm balloon. However, other patients had larger esoph-
ageal diameters and the 28-mm (n 2) or 31-mm (n 3)
alloon electrodes were used.
There were no surgical or endoscopic complications and
lood loss was 50 mL in all cases. Eight patients were
ischarged home on postoperative day 1 and 2 at 48 hours
ecause of transportation issues. There were no readmis-
ions or acute perioperative problems.
Symptomatic evaluation
Patients were seen between 2 and 4 weeks postoperatively
for acute recovery data, including pain control, diet pro-
gression, and other subjective data. Results of the symptom
questionnaire are shown in Figure 3.
BE resolution
Long-term follow-up ranged from 7 months to 28 months
(mean 17 months). All patients completed their 6-month
comprehensive evaluation, 8 completed their 1-year evalu-
ation, and 4 completed a 24-month follow-up.
All patients were free of BE at time of last follow-up.
One had biopsies with columnar epithelium, but no intes-
tinal metaplasia. Six patients (60%) had 100% resolution
of their BE after 1 intraoperative ablative treatment per-
formed at the time of their fundoplication (Table 3). This
included 4 patients who had failed previous multiple at-
tempts at ablation. None of the remaining BE patients had
dysplasia. The remaining 4 patients had a 50% resolu-
tion and underwent endoscopic ablation. At their second
follow-up endoscopy, 3 patients were found to have resid-
ual BE, however, their overall disease burden was less. A
Figure 3. Postoperative patient symptomatic evaluation at 2 to 4
eeks. White bar, absent; black bar, present.third ablation succeeded in complete control, although 1 kpatient continued to have columnar epithelium with no
intestinal metaplasia at 24-month follow-up.
Two patients had major complications related to the
ablation treatments. One patient had a soft stricture noted
at their first diagnostic endoscopy performed on postoper-
ative day 48 for mild solid-food dysphagia. A second pa-
tient was evaluated at 6 weeks postoperatively because of a
report of a food impaction.This patient was evaluated with
upper endoscopy and was found to have a 1.5-cm perfora-
tion within the proximal RFA field.
There were no particular postoperative complications
attributable to the fundoplication, although patients fre-
quently noted common side effects, such as early satiety,
bloating, and flatulence. At longest follow-up, no patients
had reflux complaints and 1 patient reported heartburn.
Three patients were on peptic medications. All fundopli-
cations were intact (Hill grade I) on last endoscopy. Eight
patients had postoperative manometry and pH studies and
all results were within the normal range, including the 1
patient with heartburn and all 3 patients on proton pump
inhibitors postoperatively.
DISCUSSION
Treatment of BE with endoscopic RFA is a relatively new
concept. The technique so far has been reported to be both
effective and well-tolerated.10,11 Exact indications for its
se, however, have yet to be worked out completely and the
ong-term efficacy of endoscopic ablations remains un-
Table 3. Endoscopic Evaluation Results of Barrett Esopha-
gus Resolution Status Post Combined Therapy
Patient
no.
Days
post-
operation
%
Resolution Complication
Hill grade
fundoplication
1 205 100 No 1
2 48 100 Yes, stricture* 1
3 90 50 No 1
159 75 No 1
220 100 No
4 78 85 No 1
166 95 No 1
249 100 No
5 42 100 Yes, perforation 1
6 202 100 No 1
7 186 100 No 1
8 187 50 No 1
255 100 No 1
9 190 100 No 1
10 60 80 No 1
376 100* No 1
*Columnar epithelium without intestinal metaplasia.nown. The cost-effectiveness of this treatment is also a
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effectiveness of the procedure rely primarily on the success
rate of BE eradication; how many treatments it takes to
achieve eradication; and how long the BE stays ablated.
The literature describes a 95% eradication rate after an
average of 2 to 6 treatments.6,12,14 Anecdotally, however,
ost practitioners have encountered a substantial number
f patients who seemingly cannot be ablated despite mul-
iple treatment sessions. At our high-volume center (250
FA procedures), we have had 1 patient referred to us after
6 ablation attempts and another after 12. Even with our
xperience, we have had occasions where as many as 5
blations failed to achieve clearance. Considering the stan-
ard protocol of treatment with RFA, reassessment 2 to 3
onths later and retreatment if there is residual disease,
nterspersed with occasional endoscopies for biopsy evalu-
tion, it is easy to understand the enormous health care
urden that multiple treatment sessions impose on the pa-
ient, practitioner, and health system.
In our experience, multiple sessions of endoscopic RFA
ere most often needed for patients who had anatomic
istortion of their distal esophagus because of hiatal her-
ias, chronic peptic scarring, or esophageal dilation and
ortuosity.We therefore theorized that laparoscopically dis-
ecting and freeing the distal esophagus would allow us to
traighten it and make its lumen more uniform. This, in
urn, would allow us to better visualize endoscopically the
sophageal mucosa, more accurately calibrate balloon sizes,
nd more effectively deliver radiofrequency energy to the
E lesions. In fact, our study shows that even in patients
ho had failed multiple treatments, the majority of the
tudy patients had complete resolution of BE after 1 intra-
perative ablation session using this intraoperative strategy.
We also like the idea of leaving a patient with a mechan-
cal reflux barrier at the completion of their myotomy. It is
resumed, but not known at this time, that the neosqua-
ous mucosa after BE ablation will have the same genetics
s the original esophagus and, therefore, be at high (per-
aps inevitable) risk of reconverting to BE and possible
ysplasia unless something additional is done to prevent it.
n intact fundoplication is well known to give patients a
upraphysiologic reflux barrier that probably would have
n impact on the genetic predisposition to metaplastic
ransformation. Whether medical therapy would have the
ame effect is controversial. There is much evidence that
ould support BE progression, even in the face of medical
reatment or perhaps because of it. We do plan to follow
his patient cohort, as well as our medically treated pa-
ients, for the long-term to document the rate of BE recur-
ence in both groups.
Although the combined procedure required more oper- gtive time (154 minutes) than an average fundoplication
ase, the overall cost savings to the patient, physician, and
ealth care system as a whole could be substantial. If BE
ould be eliminated in 20% of chronic reflux patients using
0% fewer resources and personnel, the longer operative
ime and initially higher procedure costs would yield large
ost savings overall.
Poor understanding of the genetic pathways of BE neo-
enesis results in our incomplete knowledge of how to best
reat histologic subtypes of BE.15,16 In this study, 2 patients
(patients 3 and 4) required 2 ablations, even with intra-
operative mobilization. Both of these patients’ initial pa-
thology was nondysplastic BE. There were no significant
differences in the endoscopic RFA portion of these 2 cases.
Despite no notable difference from the other study patients
who achieved complete ablation in 1 session, these 2 pa-
tients had persistent BE. Besides technical error, a possible
explanation for the different response to treatment could
be the genetic profile of the patients. It might be that they
possess proto-oncogenes or RNA triggers that make their
BE cells more resistant to radiofrequency energy, or make
regenerating neomucosa more likely to go down the BE
pathway. A better understanding of genetic predisposition
and therapeutic sensitivities is certainly needed in BE
patients.
The complication rate for our study was 20% (2 pa-
tients), indicating that the combined procedure is fairly
well tolerated. Individually, laparoscopic ARS and endo-
scopic RFA treatment are acceptably safe and have a com-
plication rate10%.The patient in whom theminor stric-
ture developed was minimally symptomatic, underwent a
single dilation, and has not had any residual symptoms.
The other complication, necrotic perforation, is more wor-
risome. The national BARRX registry had not previously
reported any perforations related to its device and no other
authors have described this phenomenon.6, 9,17 Our patient
n whom a perforation developed was an octogenarian who
ad a 13-cm length of BE. His procedure was uneventful
nd he recovered without incident. He presented 6 weeks
ater with a report of progressive dysphagia and food im-
action. Endoscopy revealed a 1.5-cm necrotic perforation
cm above the lower esophageal sphincter (LES). A con-
rast study confirmed a contained, self-draining perfora-
ion. This patient was treated conservatively and dis-
harged to home on a liquid diet and oral antibiotics. After
months, endoscopy showed complete healing of his
sophagus, no BE, and an intact fundoplication. He was
dvanced to a regular diet and has subsequently done well.
e now treat long segments in a staged fashion.The overall
issue quality in these patients with long-standing disease is
enerally poor, distal esophageal mobilization can be diffi-
492 Goers et al Treatment of Barrett Esophagus J Am Coll Surgcult and result in tissue damage and thinning of the esoph-
ageal wall. With this, radiofrequency energy application
overall distance can compromise tissue microvasculature
and result in easier necrosis. Because of these concerns, we
currently limit our ablations to lesions5 cm or we will do
them in a planned staged program.
Despite these questions, there is little doubt that RFA for
BE has dramatically altered the treatment paradigm for
dysplastic BE and has resulted in the sparing of many an
esophagus that would have otherwise been removed for this
problem. The purpose of this study was to use endoscopic
ablative technology in conjunction with laparoscopic ARS
to improve electrode contact, thereby increasing the success
rate of complete ablation.We show that this improves over-
all BE ablation efficiency, decreases BE recurrence, and will
hopefully impact long-term cancer risk.
CONCLUSIONS
Intraoperative endoscopic RFA of BE at the time of lapa-
roscopic fundoplication is feasible and might be a more
efficient and cost-effective way to treat BE.We show that a
single combined treatment results in the need for fewer
overall procedures performed to obtain BE eradication. Al-
though the complication rate of this pilot study was not
negligible, patients did well with conservative treatment
and our procedural approach has been subsequently mod-
ified with promising results. We believe that prospective
study of this combined treatment modality for patients
with BE is warranted.
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